Finally, in a clinical trial (NCT01865617) which investigated the effectiveness of CD19-redirected CAR-T cells against B-cell acute lymphoblastic leukemia (B-ALL), Turtle et al. noted a CD8+ T-cell-mediated immune response against adoptively transferred cells expressing the synthetic receptor. The gene discussed is CD8A; the disease is acute lymphoblastic leukemia.